Co-Diagnostics Inc. Acquires Suite of Technologies from DNA Logix
News May 01, 2013
Molecular diagnostics is the fastest growing segment of the $33 billion U.S. in-vitro diagnostics market. The technology to be acquired is embodied in three patent applications and certain trade secrets that enable high performance DNA testing with superior sensitivity and specificity. The technology facilitates rapid assay development and significantly reduced costs for the end user.
Dwight Egan, President of Co-Diagnostics, Inc., commented: “We are pleased to announce this technology acquisition from DNA Logix. DNA Logix’s experience in providing the technology for developing molecular diagnostics in the oncology and infectious disease arena is increasingly being recognized by major diagnostic manufacturers and pharmaceutical partners throughout the world. With this technology, we believe our highly efficient assay development capability, combined with superior results and efficient costs, will result in our unique approach to DNA testing being sought after by developers of powerful diagnostics in a wide range of markets.”
The technology was created by Brent C. Satterfield, Ph.D., founder of DNA Logix. Prior to founding DNA Logix, Dr. Satterfield helped to found Arcxis Biotechnologies with several of his inventions, including microfluidic sample preparation, diagnostic tests, and probe technologies. One of his more notable inventions was the Tentacle Probe, a new class of DNA diagnostic probe that is up to 200 times faster than other probes, up to 10,000 times more specific in high concentrations of contaminant, and up to 13 times more robust in extreme temperature conditions. His diagnostic design abilities have been utilized by a number of large organizations, including the directors and managers of Sandia National Laboratories, United States Army Medical Research Institute of Infectious Disease, Department of Homeland Security, National Biodefense Analysis and Countermeasures Center, and numerous others.
Improved Method for Isolating Extracellular RNANews
In a breakthrough that could lead to powerful new ways to diagnose and track a wide range of medical conditions, scientists at The Rockefeller University have devised an improved method for isolating and identifying tiny fragments of RNA in human blood products.READ MORE
Giant Viruses Invent Their Own GenesNews
Three new members have been isolated and added to the Pandoravirus family. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised scientists when they were discovered a few years ago. This new study notes that pandoraviruses appear to be factories for new genes – and therefore new functions.
Therapeutic CRISPR Could Be Cancer RiskNews
Therapeutic use of gene editing with the so-called CRISPR-Cas9 technique may inadvertently increase the risk of cancer, according to a new study. Researchers say that more studies are required in order to guarantee the safety of these ‘molecular scissors’ for gene-editing therapies.
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018
International Conference on Central Nervous System and Therapeutics
Nov 12 - Nov 14, 2018